Evidence map›Paper›PMID 32758249›Full record

ArticleReproductive biology and endocrinology : RB&E2020

Intra-ovarian injection of platelet-rich plasma into ovarian tissue promoted rejuvenation in the rat model of premature ovarian insufficiency and restored ovulation rate via angiogenesis modulation.

Shahin Ahmadian, Sepideh Sheshpari, Mohammad Pazhang, Alberto Miranda Bedate, Rahim Beheshti, Mehran Mesgari Abbasi, Mohammad Nouri, Reza Rahbarghazi, Mahdi Mahdipour

Open access · goldAbstract read
In one paragraph

Article in Reproductive biology and endocrinology : RB&E, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Shahin AhmadianWomen's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, 5138663134, Iran.
Sepideh SheshpariDepartment of Midwifery, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, 5138947977, Iran.
Mohammad PazhangDepartment of Biology, Faculty of Basic Sciences, Azarbaijan Shahid Madani University, Tabriz, 537517169, Iran.
Alberto Miranda BedateLaboratory for Translational Immunology (LTI), Universitair Medisch Centrum Utrecht, (UMCU), Utrecht, Heidelberglaan 100, 3584, CX, The Netherlands.
Rahim BeheshtiDepartment of Veterinary Science, Islamic Azad University Shabestar Branch, Shabestar, 5381637181, Iran.
Mehran Mesgari AbbasiDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohammad NouriStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, 5165665811, Iran.
Reza RahbarghaziStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, 5165665811, Iran.
Mahdi MahdipourStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, 5165665811, Iran. mahdipourm@tbzmed.ac.ir.ORCID http://orcid.org/0000-0002-2729-4593
Tabriz University of Medical Sciences · IRAzarbaijan Shahid Madani University · IRIslamic Azad University Shabestar · IRUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Premature Ovarian Insufficiency (POI) is viewed as a type of infertility in which the menopausal status occurs before the physiological age. Several therapeutic strategies have been introduced in clinic for POI treatment, although the outputs are not fully convincing. Platelet-rich plasma (PRP) is a unique blood product widely applied in regenerative medicine, which is based on the releasing of the growth factors present in platelets α-granules. In the current investigation, we examined the effectiveness of PRP as a therapeutic alternative for POI animals. POI in Wistar albino rats was induced by daily intraperitoneal (IP) administration of gonadotoxic chemical agent, 4-vinylcyclohexene dioxide (VCD) (160 mg/ kg) for 15 consecutive days. After POI induction, the PRP solution was directly injected intra-ovarian in two concentrations via a surgical intervention. Every two weeks post-injection, pathological changes were monitored in the ovaries using Hematoxylin-Eosin staining method, until eight weeks. Follicle Stimulating Hormone (FSH) content in serum was measured, together with the expression of the angiogenic-related transcripts ANGPT2 and KDR by real-time qPCR. Furthermore the fertility status of the treated rats was evaluated by mating trials. Histopathological examination revealed successful POI induction via the depletion of morphologically normal follicles in rats following VCD treatment compared to the control rats. The injection of PRP at two concentrations reduced the number and extent of the follicular atresia and inflammatory responses (p < 0.05). The expression of both ANGPT2 and KDR transcripts were significantly increased in POI rats due to enhanced inflammation, while these values were modulated after PRP administration (p < 0.05) compared to POI rats. FSH showed a decreased trend in concentration eight weeks after PRP treatment, but not statistically significant (p > 0.05). Nevertheless, a clear improvement in litter counts was found in POI rats receiving PRP compared to the non-treated POI group, being able to consider PRP as a facile, quick, accessible, safe and relatively cheap alternative therapeutic strategy to revert POI-related pathologies.

Indexed as

OvaryAngiogenesis Modulating AgentsAnimalsDisease Models, AnimalFemaleInjections, IntralesionalNeovascularization, PhysiologicOvulationPlatelet-Rich PlasmaPrimary Ovarian InsufficiencyRatsRats, WistarRecovery of FunctionRejuvenationAngiogenesis Modulating AgentsAngiogenesisFertilityOvarian rejuvenationPlatelet-rich plasmaPremature ovarian insufficiency

Identifiers

PMID32758249
PMCPMC7405361
OpenAlexW3047139656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.